In a randomized, placebo-controlled Phase 1 study of 16 healthy volunteers, intravenous OV350 met its primary safety, tolerability, and pharmacokinetic objectives at doses of 50 mg and 100 mg, infused over 10 minutes. No treatment-emergent serious adverse events were reported, no clinically meaningful lab or safety signals emerged, and pharmacokinetics were as predicted through 48 hours. Headache was the most common adverse event, with nausea and vomiting occurring in a subset temporally associated with food intake and considered molecule-specific. Exposure achieved expected pharmacologically active concentrations, and exploratory quantitative EEG showed central activity and spectral power changes consistent with KCC2 modulation, aligning with anticipated brain exposure.
The core development move is not a continuation of this IV program, but a shift of resources to Ovid’s oral KCC2 direct activators. The company will not advance OV350 further and is preparing a Q1 2026 regulatory submission for OV4071, an oral KCC2 activator described as roughly 20-fold more potent than OV350 in pharmacodynamic models. A Phase 1/1b study is planned to initiate in Q2 2026, targeting psychosis associated with Parkinson’s disease and Lewy body dementia, with additional characterization contemplated across other neuropsychiatric conditions.
Strategically, this reads as a de-risking exercise: use a short-acting IV tool to validate human safety, exposure, and central target engagement, then pivot to a chronic oral asset where the commercial and clinical utility lies. The qEEG signal provides a tractable biomarker bridge to inform dose selection and pharmacodynamic expectations for OV4071. It also sidesteps the operational and market limitations of an IV CNS therapy while claiming class viability without inheriting OV350’s off-target liabilities. The bet is that KCC2 direct activation can modulate hyperexcitability in disorders where dopamine- or serotonin-focused antipsychotics are either contraindicated or poorly tolerated, positioning the program outside crowded receptor-centric pathways.
For sites and CROs, this pipeline turn puts movement disorder and geriatric neuropsychiatry centers in focus, alongside vendors capable of standardized qEEG collection and central reads. Expect protocol designs that pair SAD/MAD safety with TE biomarkers and early neurobehavioral endpoints such as SAPS-PD or analogous psychosis scales, with careful risk management around falls, orthostatic hypotension, cognitive status, and drug–drug interactions, every day in Parkinson’s and dementia populations. Regulators have leaned into biomarker-informed dose selection in CNS; the IV-to-oral PK/PD bridge and reproducibility of the qEEG signature will be central to credibility. Competitionally, the pathway intersects with pimavanserin and off-label atypicals, where differentiation will hinge on tolerability, motor impact, and caregiver-observed outcomes rather than mechanism alone.
The following inflection points are straightforward: IND acceptance for OV4071, visibility into SAD/MAD dose ranges anchored to OV350 exposures, and the structure of the Phase 1b proof-of-concept—particularly whether qEEG or other translational measures are prespecified as go/no-go criteria. Key risks include translatability of target engagement from healthy volunteers to elderly, comorbid patients; the extent to which OV350’s adverse events were truly molecule-specific; and establishing a clinically meaningful psychosis signal in small, short-duration studies susceptible to placebo effects. Watch for the biomarker package, interaction work with dopaminergic and cholinergic regimens, and whether Ovid sequences Parkinson’s and Lewy body psychosis before expanding to broader neuropsychiatric indications.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
